FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.

The U.S. Food and Drug Administration now requires and has approved safety labeling changes to the prescribing information ...

The prescribing information for two respiratory syncytial virus (RSV) vaccines will now include a warning for the increased ...

The prescribing information for Abrysvo ® (respiratory syncytial virus [RSV] vaccine) and Arexvy ® (RSV vaccine, adjuvanted) has been updated to include a new warning regarding the risk of ...

It's recommended those who are between 32 weeks and 36 weeks pregnant get one dose of the maternal RSV vaccine, Abrysvo, administered September through January. Adults 75 and older and those 60-74 ...

Women who are 28-36 weeks pregnant will have access to the Pfizer-made Abrysvo vaccine, which would normally come at a cost of up to $300. Women who are 28-36 weeks pregnant will have access to ...

recommend those between 32 weeks and 36 weeks pregnant get one dose of the maternal RSV vaccine, Abrysvo, administered from September through January.

According to the FDA, the benefits of vaccination with Abrysvo and Arexvy continue to outweigh the potential risks. The prescribing information for Abrysvo ® (respiratory syncytial virus [RSV ...